Zilovertamab
Based on 3 publication(s) in Google Scholar
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.21%
- CAS No.: 2485779-13-1
- 분자량:145.12 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
-
HY-P99001
Human IgG1 kappa, Isotype ControlIgG1κ Isotype Control -
HY-P9904
AtezolizumabAnti-PD-L1 Antibody -
HY-P99367
IfinatamabAnti-Human B7-H3 Antibody -
HY-13629
EtoposideTopoisomerase II Inhibitor -
HY-P9966
EnoblituzumabB7-H3 mAb -
HY-148439
DaraxonrasibRAS(ON) Inhibitor -
HY-P9905
CetuximabEGFR Inhibitor -
HY-14422
SR1078RORα/RORγ Agonist -
HY-125801
3-Oxo-5β-cholanoic acidTH17 Cell Differentiation Inhibitor -
HY-119738
OSMI-1O-GlcNAc Transferase Inhibitor -
HY-12305
Q-VD-OPhPan-caspase Inhibitor
Publications Citing Use of MedChemExpress (MCE) Zilovertamab
More
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
Wnt5A |
In Vitro
Zilovertamab (25 and 50 μg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation[1].
Zilovertamab (50 μg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CaOV3, CaOV3CisR, PEO1, and PEO4 cells
-
Concentration:25 and 50 µg/mL
-
Incubation Time:72 hours
-
Result:Reduced the proliferation of CaOV3, CaOV3CisR and PEO1.
-
Cell Line:CaOV3, CaOV3CisR, PEO1, and PEO4 cells
-
Concentration:50 µg/mL
-
Incubation Time:72 hours
-
Result:Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Q01973
Target
ROR1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human ROR1-ECD-His can bind Zilovertamab. The EC50 for this effect is 3.078 ng/mL.
Chemical Information
-
CAS No. 2485779-13-1
-
Appearance Liquid
-
분자량 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Zilovertamab]
-
Synonyms
UC-961; Cirmtuzumab
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Mol Ther
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. [Abstract]2025 Dec 2:S1525-0016(25)00959-1. PMID: 41338184 -
-
순도&문서
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zilovertamab Related Classifications
HY-P99201 Related Classifications
Powered by Bioz